R J Biotech Limited reported audited standalone earnings results for the half year and year ended March 31, 2018. For the half year, the company reported total revenue of INR 18.24 million, loss before exceptional items and extraordinary items of INR 85.805 million, loss from ordinary activities before tax of INR 174.124 million, net loss of INR 174.124 million or INR 36.88 basic and diluted per share compared to the total revenue of INR 0.947 million, loss before exceptional items and extraordinary items of INR 128.153 million, loss from ordinary activities before tax of INR 128.157 million, net loss of INR 128.159 million or INR 27.15 basic and diluted per share for the same quarter a year ago. For the year, the company reported total revenue of INR 90.276 million, loss before exceptional items and extraordinary items of INR 119.348 million, loss from ordinary activities before tax of INR 207.666 million, net loss of INR 207.666 million or INR 21.93 basic and diluted per share compared to the total revenue of INR 157.383 million, loss before exceptional items and extraordinary items of INR 150.74 million, loss from ordinary activities before tax of INR 150.169 million, net loss of INR 150.17 million or INR 15.86 basic and diluted per share for the previous year.